QDEL Key Statistics, Chart & Performance
The current stock price of QDEL is 26.58 USD. In the past month the price decreased by -9.84%. In the past year, price decreased by -35.17%.
QDEL Latest News, Press Relases and Analysis
QDEL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.49 | 221.37B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.03 | 203.79B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.23 | 145.27B | ||
| SYK | STRYKER CORP | 28.11 | 141.54B | ||
| IDXX | IDEXX LABORATORIES INC | 59.65 | 60.17B | ||
| BDX | BECTON DICKINSON AND CO | 13.24 | 54.73B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.96 | 49.16B | ||
| RMD | RESMED INC | 25.31 | 36.56B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.05 | 35.64B | ||
| DXCM | DEXCOM INC | 33.45 | 24.40B | ||
| PODD | INSULET CORP | 73.86 | 23.75B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.56 | 18.53B |
Related stock screener links
About QDEL
Company Profile
QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,600 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
Company Info
QUIDELORTHO CORP
9975 Summers Ridge Road
San Diego CALIFORNIA 92121 US
CEO: Douglas C. Bryant
Employees: 6600
Phone: 18585521100
QUIDELORTHO CORP / QDEL FAQ
Can you describe the business of QUIDELORTHO CORP?
QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,600 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
What is the stock price of QUIDELORTHO CORP today?
The current stock price of QDEL is 26.58 USD. The price increased by 9.16% in the last trading session.
Does QDEL stock pay dividends?
QDEL does not pay a dividend.
How is the ChartMill rating for QUIDELORTHO CORP?
QDEL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of QUIDELORTHO CORP (QDEL) based on its PE ratio?
The PE ratio for QUIDELORTHO CORP (QDEL) is 11.61. This is based on the reported non-GAAP earnings per share of 2.29 and the current share price of 26.58 USD.
How many employees does QUIDELORTHO CORP have?
QUIDELORTHO CORP (QDEL) currently has 6600 employees.
When does QUIDELORTHO CORP (QDEL) report earnings?
QUIDELORTHO CORP (QDEL) will report earnings on 2026-02-11, after the market close.
QDEL Technical Analysis
QDEL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to QDEL. Both the profitability and financial health of QDEL have multiple concerns.
QDEL Financial Highlights
Over the last trailing twelve months QDEL reported a non-GAAP Earnings per Share(EPS) of 2.29. The EPS decreased by -4.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.78% | ||
| ROE | -57.9% | ||
| Debt/Equity | 1.23 |
QDEL Forecast & Estimates
14 analysts have analysed QDEL and the average price target is 37.59 USD. This implies a price increase of 41.44% is expected in the next year compared to the current price of 26.58.
For the next year, analysts expect an EPS growth of 14.78% and a revenue growth -2.4% for QDEL